Grauer & Weil Share Price Today and Targets for 2026 to 2030
- Market Cap
- ₹3,294 Cr
- Book Value
- ₹23.9
- Stock P/E
- 20.56
- Dividend Yield
- 0.70%
- ROE
- 15.20%
- ROCE
- 20.60%
- PEG Ratio
- 1.96
- EV/EBITDA
- 12.9
Fundamentals from Screener.in, as of 10 Sep 2026. Live price via Yahoo Finance.
Grauer & Weil share price today
Most people who search for the Grauer & Weil share price are looking at a company that sits underneath the visible economy rather than inside it. Grauer & Weil (India) makes the electroplating and surface-finishing chemicals that go on to a bathroom fitting, a fastener, a bearing, a connector or a car component before anyone sees the finished product. Incorporated in 1957 and trading under the Growel brand, it also runs an engineering arm and, unusually for a chemicals company, owns a mall.
At the 10 September 2026 research cut-off, the stock closed at about ₹72.58 on the BSE, giving a market capitalisation of roughly ₹3,294 crore against trailing EPS of ₹3.53. That is about 20.6 times trailing earnings and 3.06 times a book value of ₹23.9. The quote above updates after publication; every ratio and scenario input below stays fixed to that cut-off.
The tension in the shares is visible in one comparison. Sales have kept compounding — the trailing twelve months show ₹1,236 crore against ₹1,190 crore in FY26 — but trailing net profit of ₹160 crore is slightly below the FY26 figure of ₹164 crore, and the operating margin has drifted from 18% in FY24 to 15% on a trailing basis. The share price has fallen about 24% over the past year and sits roughly 23.7% below its 52-week high. The question is whether that is a pause in a good compounder or the market repricing a slower one.
What Grauer & Weil actually sells
The company describes itself as a surface-finishing solutions business. In plain terms, it supplies the chemistry, the equipment and the process know-how that put a durable, corrosion-resistant layer on metal and plastic parts. Its own material notes that Growel was the first Indian surface-finishing company to carry AS 9100 certification and that it is among a small global group offering complete corrosion-protection solutions across all substrates.
| Vertical | Representative offering | Customer problem solved | Economic characteristic |
|---|---|---|---|
| Surface finishing chemicals | Electroplating and specialty chemicals, zinc flake coatings, phosphating and anodizing | Making a metal part resist corrosion and wear | Consumable, repeat-purchase, specification-locked |
| Paints and coatings | Protective, automotive, marine, architectural and pipe coatings | Protecting and finishing large fabricated assets | Project and industrial demand, raw-material sensitive |
| Lubricants | Rust preventives, cutting oils, wire-drawing and forming fluids | Keeping metalworking processes running cleanly | Consumable, tied to factory utilisation |
| Engineering | Turnkey surface-finishing plants, effluent and waste-water treatment | Installing and running the process, not just supplying it | Order-driven, lumpier than chemicals |
| Real estate | The Shoppertainment segment reported by the company | Unrelated to the chemicals franchise | Rental-style income inside an industrial company |
The chemistry business is where the durable economics sit. Once a customer’s plating line, quality approvals and audit trail are built around a supplier’s chemistry, switching is disruptive and rarely worth the saving on a small consumable. That is the mechanism behind a 20.6% return on capital employed and a five-year average nearer 22.7%. The end-market list is genuinely broad — automotive and auto ancillaries, fasteners, bearings, sanitaryware and bath fittings, electricals, electronics and PCBs, appliances, defence and space, railways, renewable energy and general engineering — which spreads the risk of any single industry stalling.
The mall is the awkward part. A property segment inside a specialty-chemicals company absorbs capital, complicates the return calculation and gives a chemicals investor an exposure they did not ask for. It is not large enough to define the investment case, but it is large enough to explain part of why the whole company trades at a lower multiple than a pure-play chemicals peer such as Vinati Organics or Elantas Beck India.
Twelve years of revenue growth, and a recent flattening
The long record is good. Sales rose from ₹409 crore in FY15 to ₹1,190 crore in FY26, and net profit from ₹33 crore to ₹164 crore over the same span. But the shape of that growth has changed: the heavy lifting happened between FY22 and FY24, when sales went from ₹768 crore to ₹1,068 crore and profit from ₹79 crore to ₹146 crore. Since then the increments have been smaller.
| Financial year | Sales | Operating margin | Net profit | EPS | Dividend payout |
|---|---|---|---|---|---|
| FY21 | ₹605 Cr | 17% | ₹69 Cr | ₹1.52 | 16% |
| FY22 | ₹768 Cr | 15% | ₹79 Cr | ₹1.74 | 19% |
| FY23 | ₹981 Cr | 16% | ₹113 Cr | ₹2.49 | 16% |
| FY24 | ₹1,068 Cr | 18% | ₹146 Cr | ₹3.23 | 8% |
| FY25 | ₹1,133 Cr | 17% | ₹157 Cr | ₹3.47 | 14% |
| FY26 | ₹1,190 Cr | 16% | ₹164 Cr | ₹3.62 | 28% |
| Trailing twelve months | ₹1,236 Cr | 15% | ₹160 Cr | ₹3.53 | Not an annual period |
Two things stand out. First, the operating margin has given back the FY24 gain, and the trailing figure of 15% matches FY22 as the weakest in the visible series. Yahoo Finance computes 14.0% on a slightly different basis, which moves the level but not the direction. Second, trailing profit and trailing EPS are both marginally below the FY26 annual figures even though trailing sales are higher — growth is arriving with less profit attached to it. Yahoo Finance frames the same point differently, showing year-on-year revenue growth of 17.9% alongside earnings growth of −8.3%.
The payout ratio also jumped to 28% in FY26 from 8% in FY24. A company that raises the share of profit it hands back is often signalling that it has more cash than immediate reinvestment ideas, which is comfortable for an income holder and less exciting for someone underwriting rapid compounding.
The compounding rate is slowing on every horizon
| Measure | 10-year | 5-year | 3-year | Most recent |
|---|---|---|---|---|
| Sales CAGR | 11% | 14% | 7% | 10% (TTM) |
| Profit CAGR | 13% | 18% | 11% | 7% (TTM) |
| Share price CAGR | 17% | 20% | 2% | −24% (1 year) |
| Return on equity | 17% | 17% | 17% | 15% (last year) |
The compounding table is the most useful piece of evidence on this page. Every horizon tells the same story, and the three-year column is where it turns: sales compounding at 14% over five years but only 7% over three, profit at 18% against 11%. The share price compounded at 20% a year over five years and at 2% over three, which tells you the de-rating has already started — investors have spent three years absorbing the gap between the five-year record and the three-year one.
Return on equity is the steadiest number here: 17% across ten, five and three years, easing to 15% in the latest year. That stability is the argument against treating the recent slowdown as structural damage. If you want the mechanics of why a stable ROE matters more than a single year’s profit growth, our guide to return on equity sets out the arithmetic.
A balance sheet with almost nothing to worry about
| Balance-sheet signal | FY24 | FY25 | FY26 | Why it matters |
|---|---|---|---|---|
| Reserves | ₹783 Cr | ₹894 Cr | ₹1,036 Cr | Profit is being retained, not leaked |
| Borrowings | ₹27 Cr | ₹12 Cr | ₹15 Cr | Debt is a rounding error against equity |
| Total assets | ₹1,124 Cr | ₹1,286 Cr | ₹1,445 Cr | The asset base is still being expanded |
| Equity capital | ₹23 Cr | ₹45 Cr | ₹45 Cr | Roughly doubled in FY25; check the corporate-action history before comparing old per-share figures |
Debt-to-equity is 0.01. Yahoo Finance reports total cash of about ₹455 crore against total debt of about ₹15 crore, so the company holds roughly ₹440 crore of net cash — near 13% of its market capitalisation. Promoter pledging is zero.
That combination changes the character of the risk. A leveraged micro-cap with slowing profit growth has a solvency problem; a net-cash one has a returns problem. Grauer & Weil has the second, not the first. The cash also means the enterprise value is materially smaller than the market capitalisation, which is why EV/EBITDA of 12.9 looks less demanding than the 20.6 P/E on its own does.
One presentational note: the equity capital line roughly doubled between FY24 and FY25 with a face value of ₹1. Anyone comparing per-share numbers across that boundary should confirm the corporate-action history on the company’s own investor disclosures rather than assuming the series is like-for-like.
Where the Grauer & Weil share price sits against its own range
Yahoo Finance puts the 52-week band at ₹51.57 to ₹95.09, with the current price about 23.67% below the high. Screener’s page shows a slightly different band — a ₹96.8 high and a ₹49.7 low — which is a normal consequence of the two services measuring intraday versus closing extremes. Either way, the stock has round-tripped a wide range in a year and is currently nearer the middle of it than the top.
There is one structural detail worth knowing before looking at a chart. The shares trade on both exchanges — BSE scrip 505710 and NSE symbol GRAUWEIL — so the order book is not confined to a single venue. What does constrain it is size: a ₹3,294 crore company with institutional holding of 0.40% is thinly traded by the standards of the screens most investors use. Spreads widen and fills slow in exactly the periods when the price is moving most, for reasons that have nothing to do with the business.
Ownership is concentrated and institutions are effectively absent
| Holder group | Share of equity, Screener basis |
|---|---|
| Promoters | 69.04% |
| Foreign institutional investors | 0.35% |
| Domestic institutional investors | 0.05% |
| Public and others | 30.55% |
| Promoter shares pledged | 0.00% |
A 69% promoter holding with no pledging is a strong alignment signal. The near-total absence of institutions — 0.40% between FIIs and DIIs — cuts both ways: there is no institutional stamp of approval, but there is also no crowded institutional position that could unwind quickly.
Note one discrepancy between the two data services. Yahoo Finance reports promoter holding of 72.57% while Screener’s shareholding pattern shows 69.04%. The two services classify promoter-group entities differently and update on different schedules. The number to trust is whichever appears in the shareholding pattern filed by the company itself.
Valuation at the research cut-off
| Valuation measure | 10 September 2026 reading | Interpretation |
|---|---|---|
| Closing price | ₹72.58 | Fixed research input, not a live figure |
| Market capitalisation | ₹3,294 Cr | Micro-cap; day-to-day liquidity is thin |
| Trailing EPS | ₹3.53 | Screener TTM basis |
| Recalculated P/E | 20.56× | Price divided by trailing EPS |
| Book value per share | ₹23.9 | Price-to-book of 3.06× |
| EV/EBITDA | 12.9 | Lower than the P/E because of the net-cash position |
| PEG | 1.96 | Growth is not cheap relative to the multiple |
| Dividend yield | 0.70% | Real, but small against the total-return arithmetic |
| ROCE / ROE | 20.60% / 15.20% | Genuinely good returns on capital |
| 52-week range | ₹51.57 – ₹95.09 | About 23.67% below the high |
Twenty times earnings is not an expensive multiple for a business earning 20% on capital with net cash and near-zero debt. It is also not obviously cheap when three-year profit growth is 11% and the trailing twelve-month profit is slightly below the last full financial year. PEG of 1.96 puts the same point in one number. If you want the underlying method, our note on how to value a stock explains the framework used across this site, and the P/E ratio guide covers where the multiple breaks down.
Valuation framework
The scenario model starts with TTM EPS of ₹3.53. For each year it applies EPS_TTM × (1 + growth)^(year − 2026 + 112/365) × exit P/E, then rounds the result to the nearest ₹1. The 112/365 factor represents the fraction of the first forecast year remaining from 10 September to 31 December. Dividends are excluded.
| Scenario | Annual EPS growth | Exit P/E | Business interpretation |
|---|---|---|---|
| Bear | 7% | 14× | Margin stays near 15%, the three-year slowdown persists, and the market rates a slow chemicals company with a mall attached accordingly |
| Base | 11% | 19× | Growth settles at the three-year profit CAGR, margin stabilises, and the multiple holds close to today’s |
| Bull | 15% | 24× | Volume growth returns toward the five-year rate, margin recovers toward FY24 levels, and the net-cash balance sheet earns a modest re-rating |
The growth rates are deliberately anchored on the three-year record rather than the five-year one, because the five-year figure includes a post-pandemic recovery base that will not repeat. The multiples are anchored below, at and modestly above the current 20.56×. A model that assumed the five-year growth rate and a large permanent re-rating at the same time would be arguing for the same thing twice.
Grauer & Weil share price target 2026 to 2030
The grid above is generated only from the disclosed EPS, growth and exit-multiple inputs, applied mechanically across the five years. It does not model the segment mix between chemicals, engineering and real estate, a change in the raw material cycle, an equity issue or buyback, a property revaluation, an acquisition, or any use of the ₹455 crore cash pile. Those inputs would need to be updated before the framework is applied to a later set of results.
Risks that can break the thesis
The first risk is margin. Operating margin has moved from 18% in FY24 to 15% on a trailing basis, and specialty-chemicals margins are exposed to input costs the company does not control. A second consecutive year of margin compression would undermine the growth assumption in every scenario, not just the bear one.
The second is customer concentration by industry rather than by name. The end-market list is long, but a large share of surface-finishing demand tracks automotive, auto ancillaries and general engineering output. An industrial slowdown reaches this company through volume before it reaches it through price.
The third is the real-estate segment. It ties up capital in an asset class with different economics, different cycles and different disclosure needs from the chemicals business, and it makes segment-level return analysis harder for an outside investor than it should be.
The fourth is liquidity. This is a ₹3,294 crore company with 0.40% institutional ownership and roughly 30% of the equity in public hands. Thin trading widens spreads, amplifies drawdowns and can make an orderly exit slower than the market capitalisation on its own would suggest.
What would change the thesis
The case strengthens if the operating margin recovers back toward 17–18% while sales keep growing at a high single-digit to low double-digit rate, if ROCE holds above 20% as the asset base expands, and if the cash balance is deployed into surface-finishing capacity or a related chemistry business rather than sitting idle. Renewed institutional participation would also be a mild confirmation that the disclosure quality is improving.
It weakens if trailing profit keeps falling while sales rise, if the payout ratio keeps climbing without a corresponding return-on-capital story, if the real-estate segment absorbs a further round of capital expenditure, or if the three-year sales CAGR of 7% turns out to be the new normal rather than a cyclical trough. A comparable micro-cap chemicals slowdown is visible in Kronox Lab Sciences, which is worth reading alongside this one.
Monitoring scorecard
| Question | Constructive evidence | Warning sign |
|---|---|---|
| Is the margin recovering? | Operating margin back above 16% | Another year at or below 15% |
| Is profit tracking sales? | Profit growth at least matching revenue growth | Revenue up while trailing profit falls again |
| Are returns intact? | ROCE holding above 20% as assets grow | ROCE drifting toward the ROE level |
| What happens to the cash? | Deployed into chemistry capacity or capability | Balance grows while growth slows |
| Is the property segment shrinking in importance? | Chemicals share of capital employed rising | Fresh real-estate capital expenditure |
| Is the balance sheet still clean? | Borrowings near ₹15 Cr, pledging at zero | Any promoter pledge or step-up in debt |
Reading the evidence at the current price
Grauer & Weil is the kind of business that rarely produces headlines: a 1957 company with a defensible position in an unglamorous consumable, 20.6% returns on capital, ₹440 crore of net cash, no pledging and a promoter holding just under 70%. Nothing in the balance sheet threatens the shareholder.
What the numbers do not yet show is re-acceleration. Three-year sales growth of 7%, three-year profit growth of 11%, a trailing margin back at the bottom of its range and trailing profit below the last full year are all consistent with a good company growing at an ordinary rate. At 20.6 times earnings with a PEG near 2, the market is not treating that as a problem, but it is not offering much margin for error either. The evidence that would settle the question is a recovering operating margin and profit growth reconnecting with sales growth over the next two or three reported periods.
FAQ
What is Grauer & Weil’s share price target for 2026?
The 2026 figure in the scenario grid is derived mechanically from trailing EPS of ₹3.53, the three annual growth rates, the three exit multiples and the 112/365 partial-year factor for the period from 10 September to 31 December. Because only about 31% of 2026 remains from the cut-off, the 2026 column is close to the starting valuation in each scenario. It is a range of arithmetic outcomes, not a forecast of where the shares will trade.
What is Grauer & Weil’s share price target for 2030?
The 2030 column compounds the same trailing EPS forward by four and a bit years at each scenario’s growth rate before applying that scenario’s exit P/E. The spread between the bear and bull columns is wide because both the growth rate and the multiple differ across scenarios. Treat it as a sensitivity table, not a prediction.
What does Grauer & Weil do?
It manufactures and sells surface-finishing chemistry — electroplating and specialty chemicals, zinc flake coatings, phosphating and anodizing chemicals, strippers, and electronics and PCB solutions — alongside industrial paints and lubricants. It also supplies turnkey surface-finishing and effluent-treatment plants through an engineering segment, and it operates a mall reported as the Shoppertainment segment. The company was incorporated in 1957 and is headquartered in Mumbai.
What is the ROCE of Grauer & Weil?
Screener showed return on capital employed of 20.6% at the 10 September 2026 cut-off, with a five-year average of 22.66%. Return on equity was 15.2% in the latest year against a 17% average over three, five and ten years. The gap between ROCE and ROE reflects a business that carries almost no debt, so leverage does not amplify equity returns.
Who are the promoters of Grauer & Weil?
Screener’s shareholding pattern showed the promoter group holding 69.04% of the equity with none of it pledged, while Yahoo Finance reported 72.57% on a slightly different classification. Institutional holding is negligible at 0.35% foreign and 0.05% domestic. The names of the promoter-group entities appear in the shareholding pattern filed on the company’s own investor page.
Is Growel the same company as Grauer & Weil?
Yes. Growel is the brand and trade name used by Grauer & Weil (India) Limited, which is why searches for “growel share price”, “grauer and weil share price” and “grauer & weil share price” all point at the same listing — BSE scrip 505710 and NSE symbol GRAUWEIL. The company’s website is growel.com and its investor disclosures are published there under the Grauer & Weil (India) Limited name.
Related research
- Vinati Organics share price target
- Elantas Beck India share price target
- Kronox Lab Sciences share price target
- Fineotex Chemical share price target
- How to value a stock: the method behind every target here
- P/E ratio formula, meaning and limits
- Return on equity: formula and interpretation
Sources and methodology
- Grauer & Weil on Screener.in
- Grauer & Weil (India) quote and key statistics on Yahoo Finance
- Grauer & Weil company website
- Grauer & Weil investor disclosures
- Grauer & Weil financial disclosures and annual reports
All figures were captured on 10 September 2026. The annual sales, operating margin, net profit, EPS, dividend payout and balance-sheet series, the ROCE, ROE, PEG, EV/EBITDA and price-to-book ratios, the growth CAGR table and the shareholding pattern come from Screener. The closing price, 52-week range, cash and debt balances, segment description and the year-on-year revenue and earnings growth rates come from Yahoo Finance. The business and vertical descriptions come from the company’s own website and Screener’s company summary. Where the two data services disagree — on the 52-week band, on the operating margin basis and on promoter holding — both readings are stated in the body rather than averaged.
Analytical judgment begins at the scenario table. The choice of growth rates, the choice of exit multiples, the reading of the margin trend, the treatment of the real-estate segment as a valuation drag and the interpretation of the liquidity consequences of a thin micro-cap float are ours, not the sources’.
This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. The scenarios are illustrations, not guarantees. Verify current exchange filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.